Postmenopausal Bleeding in Elderly Women

Emergency Medicine Topic for MRCEM Candidates

---

Overview

Postmenopausal bleeding (PMB) is defined as vaginal bleeding occurring more than 12 months after a woman’s last menstrual period.
While benign causes are common, PMB must always be treated as malignant until proven otherwise.

In the Emergency Department (ED), PMB is a red-flag presentation requiring careful history, examination, and appropriate referral via the two-week suspected cancer pathway.

---

Key Exam Pearl

Any vaginal bleeding occurring more than 12 months after menopause should be considered endometrial cancer until proven otherwise.

NICE guidance recommends urgent (two-week) referral for all women aged 55 years and older with unexplained PMB.

---

Learning Objectives

By the end of this topic, MRCEM candidates should be able to:

• Define postmenopausal bleeding and its significance.

• Recognise common benign and malignant causes.

• Take an appropriate history and perform examination in the ED.

• Outline initial investigations and referral criteria (NICE).

• Identify red-flag features and avoid common pitfalls.

---

Epidemiology and Significance

• PMB affects around 5–10% of postmenopausal women.

• Approximately 10% of those presenting with PMB will have endometrial carcinoma.

• Risk of malignancy increases with age, obesity, diabetes, and use of unopposed oestrogen.

• According to NICE (NG12), any woman aged 55 years or older with unexplained PMB should be referred urgently (within 2 weeks).

---

Causes and Differential Diagnosis

Benign Causes

• Endometrial or vaginal atrophy (most common).

• Endometrial or cervical polyps.

• Unscheduled bleeding on hormone replacement therapy (HRT).

• Vaginal or cervical infection.

• Trauma or foreign body.

Malignant or Premalignant Causes

• Endometrial carcinoma.

• Endometrial hyperplasia (atypical).

• Cervical carcinoma.

• Vaginal or vulval carcinoma (less common).

Risk Factors for Endometrial Cancer

• Increasing age.

• Obesity.

• Diabetes mellitus.

• Hypertension.

• Tamoxifen or unopposed oestrogen therapy.

• Family history of endometrial or colorectal cancer.

---

Assessment in the Emergency Department

History

• Confirm that the patient is postmenopausal (no periods for ≥12 months).

• Characterise the bleeding: onset, duration, quantity, recurrence, post-coital?

• Medication history: HRT, tamoxifen, anticoagulants.

• Associated symptoms: pelvic pain, discharge, weight loss.

• Clarify the source of bleeding — ensure it is vaginal (not urinary or rectal).

Examination

• Record vital signs; assess for anaemia or haemodynamic instability.

• Abdominal examination for tenderness or masses.

• Pelvic/speculum examination if appropriate — look for atrophy, polyps, or suspicious lesions.

Red-Flag Features

• Any bleeding more than one year after menopause.

• Recurrent or heavy bleeding.

• Suspicious cervix or vaginal lesion.

• Palpable pelvic mass or ascites.

• Tamoxifen use or significant risk factors.

• Persistent bleeding despite prior negative investigations.

---

Investigations

Initial Tests (in ED or Urgent Outpatient)

• Full blood count (check for anaemia).

• Urea and electrolytes, coagulation profile if indicated.

• Urinalysis (to rule out haematuria).

• Pregnancy test if perimenopausal or uncertain menopausal status.

Definitive Investigations (Secondary Care)

• Transvaginal ultrasound (TVUS) – first-line imaging.

  • Endometrial thickness ≤4 mm → low risk of endometrial cancer.

  • Thickness >4–5 mm or focal lesion → requires biopsy.

• Endometrial biopsy or hysteroscopy – for tissue diagnosis.

• Cervical cytology or colposcopy – if abnormal cervix suspected.

Even with a thin endometrium, persistent or recurrent bleeding must still be investigated.
Rare (Type II) endometrial cancers can occur with a normal-appearing endometrium.

---

Management and Referral

In the Emergency Department

• Stabilise if actively bleeding: IV access, fluids, transfusion if required.

• Exclude alternative sources of bleeding (urinary or rectal).

• Explain the need for urgent follow-up and document clearly:
  “Postmenopausal bleeding – possible malignancy – urgent gynaecology referral required.”

Referral Pathway (NICE NG12)

• Women aged ≥55 years with unexplained PMB → urgent 2-week referral.

• Women <55 years → consider referral if risk factors or recurrent bleeding.

• Women on HRT → review regimen, but refer if bleeding persists beyond 6 months.

Definitive Management (Specialist Care)

• Endometrial carcinoma – surgical staging ± oncology referral.

• Endometrial hyperplasia – hormonal or surgical treatment.

• Atrophic vaginitis – local oestrogen therapy.

• Polyps – hysteroscopic removal.

---

Special Considerations in the Elderly

• Frailty and comorbidities may influence investigation and treatment choices.

• Vaginal atrophy and stenosis can make examination or biopsy challenging.

• Anticoagulants may exaggerate bleeding but should not delay referral.

• Persistent or recurrent PMB always warrants repeat evaluation.

---

Key Points for MRCEM Revision

• PMB = bleeding >12 months after last period.

• Treat as malignancy until proven otherwise.

• TVUS is first-line; >4 mm endometrial thickness requires biopsy.

• All women ≥55 years with unexplained PMB → 2-week referral.

• Persistent bleeding → re-investigate, even with thin endometrium.

---

References

• RCEM Learning. Postmenopausal Bleeding (2023).

• NICE NG12. Suspected Cancer: Recognition and Referral (2024).

• NICE NG23. Menopause: Diagnosis and Management (2024).

• NHS. Postmenopausal Bleeding – Overview (2023).

• British Menopause Society. Unscheduled Bleeding on HRT – Summary Guide (2024).